News Sentiment

PLRZ sentiment intelligence

Polyrizon Ltd. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.65 Week of 10 Jul 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

72/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+6.2% over one week, +31.6% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC Filing - Form 6-K

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 72/100 classification
One-week reaction 6.2% Price confirming higher
Trend fit Trend active 31.6% over four weeks
Fair value -96.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 21
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 7
TradingView 5
TradingKey 5
Investing.com 4
GlobeNewswire 3
MT Newswires 3
The Manila Times 3

Event Lens

What the news is about

Classified themes
Earnings 17
Market update 15
Regulatory and legal 8
Analyst action 3
Guidance 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
Stock Titan Direct company coverage

[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC Filing - Form 6-K

Polyrizon Ltd. announced that its shareholders approved all proposals at the annual general meeting held on July 13, 2026, including an amended Compensation Policy for executive officers and directors. This policy, valid for three years, ties executive pay to the company's long-t

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:00
Source
Stock Titan
Baystreet.ca Direct company coverage

Polyrizon Advances on Test Results

Polyrizon Ltd. (NASDAQ: PLRZ) saw its shares rise after announcing successful biocompatibility evaluation program results for its NASARIXTM Allergy Blocker nasal spray. All required biological safety tests met predetermined acceptance criteria, adhering to international standards

Tone
Positive 92/100
Event
Earnings
Published
02 Jul 2026 20:10
Source
Baystreet.ca
Stock Titan Direct company coverage

Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial

Polyrizon Ltd. announced successful results from its NASARIX™ Allergy Blocker nasal spray's biocompatibility evaluation program. All biological safety tests met acceptance criteria, supporting the product's safety for intranasal use. This achievement marks a significant milestone

Tone
Positive 70/100
Event
Earnings
Published
02 Jul 2026 20:09
Source
Stock Titan
Market source Direct company coverage

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

Shares of Polyrizon Ltd. (NASDAQ:PLRZ) rose 10% after its NASARIX Allergy Blocker nasal spray successfully passed key biocompatibility testing. The evaluation met all predefined acceptance criteria following international regulatory standards, marking a significant step in the pr

Tone
Positive 95/100
Event
Regulatory and legal
Published
02 Jul 2026 12:40
Source
Market source
Investing.com Direct company coverage

Polyrizon completes biocompatibility tests for allergy nasal spray

Polyrizon Ltd. announced that its NASARIXTM Allergy Blocker nasal spray successfully met all required biological safety tests under ISO 10993 standards and FDA guidance. This drug-free mucoadhesive nasal spray creates a protective barrier against airborne allergens. The company,

Tone
Positive 71/100
Event
Guidance
Published
02 Jul 2026 12:40
Source
Investing.com
Stock Titan Direct company coverage

Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans

Polyrizon (Nasdaq: PLRZ) announced the successful completion of the biocompatibility evaluation program for its NASARIX™ Allergy Blocker nasal spray. All biological safety tests met predefined acceptance criteria, aligning with international standards such as ISO 10993 and FDA gu

Tone
Positive 74/100
Event
Regulatory and legal
Published
02 Jul 2026 11:40
Source
Stock Titan
Investing.com South Africa Direct company coverage

Polyrizon stock rises on biocompatibility test results By Investing.com

Polyrizon Ltd. (NASDAQ:PLRZ) shares rose 10% after announcing successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. The comprehensive evaluation program met international standards for biological safety, including ISO 10993 series and FDA guidance.

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 11:40
Source
Investing.com South Africa
Investing.com Direct company coverage

Polyrizon stock rises on biocompatibility test results

Polyrizon's stock rose 10% after the company announced successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. The tests, conducted according to international standards, evaluated key biological safety endpoints and support the product's advancement

Tone
Positive 72/100
Event
Earnings
Published
02 Jul 2026 07:43
Source
Investing.com
TradingView Direct company coverage

Price to sales forward of Polyrizon Ltd. – NASDAQ:PLRZ

This article provides a brief snapshot of Polyrizon Ltd. (NASDAQ: PLRZ) financial information, specifically its forward price-to-sales ratio. It appears to be a stub or an incomplete data point from a financial platform like TradingView. The page lacks detailed financial data or

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 09:10
Source
TradingView
Investing.com Direct company coverage

Polyrizon receives IRB approval for nasal spray clinical trial

Polyrizon Ltd. has received central institutional review board (IRB) approval to commence its first human clinical trial for NASARIX, a nasal spray designed to block airborne allergens. This approval, granted by the BRANY Institutional Review Board, covers the study protocol and

Tone
Positive 68/100
Event
Regulatory and legal
Published
29 Jun 2026 13:40
Source
Investing.com
The Manila Times Direct company coverage

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon Ltd. announced it has received central IRB approval from BRANY Institutional Review Board for its first human clinical trial for NASARIX™, an innovative nasal spray designed to block airborne allergens. This approval marks a significant regulatory milestone, allowing th

Tone
Positive 73/100
Event
Regulatory and legal
Published
29 Jun 2026 12:40
Source
The Manila Times
Stock Titan Direct company coverage

Polyrizon clears review to start first NASARIX human allergy trial

Polyrizon (Nasdaq: PLRZ) has received central IRB approval from BRANY to commence its first human clinical trial for NASARIX™, a nasal spray allergy blocker. The study will compare NASARIX to saline in patients with seasonal allergic rhinitis, evaluating its efficacy, safety, tol

Tone
Positive 71/100
Event
Regulatory and legal
Published
29 Jun 2026 12:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ

This article focuses on the "Enterprise value to revenue forward" metric for Polyrizon Ltd. (NASDAQ:PLRZ). While the exact value is not provided in the snippet, the article appears to be a financial data presentation page from TradingView. It indicates that the markets were close

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 20:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ

This article displays the Enterprise Value to EBITDA forward for Polyrizon Ltd. (NASDAQ: PLRZ) on TradingView. It indicates that the market is closed with no trades. The content also includes various navigation and footer links.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 13:28
Source
TradingView
TradingKey Direct company coverage

Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown section for Polyrizon Ltd (PLRZ). However, it states that relevant data regarding business segments and regional revenue has not yet been disclosed by the company. The page displays current stock information for PLRZ, incl

Tone
Positive 61/100
Event
Earnings
Published
18 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Polyrizon Ltd (PLRZ) stock, focusing on its dividend history and stock split events. It states that the company has not distributed any dividends over the past five years but shows a historical merger event on May 22, 2025, with a 250-to-1 rat

Tone
Positive 61/100
Event
Deals and strategy
Published
18 Jun 2026 05:39
Source
TradingKey
Stock Titan Direct company coverage

Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform

Polyrizon (Nasdaq: PLRZ) announced the publication of a U.S. patent application for its Trap & Target™ mucoadhesive nasal drug delivery platform, patent application No. US 2024/0358741 A1. This technology uses biocompatible mucoadhesive polymers to form a durable film on mucosal

Tone
Positive 65/100
Event
Analyst action
Published
17 Jun 2026 19:39
Source
Stock Titan
The Manila Times Direct company coverage

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Polyrizon Ltd. announced the publication of a U.S. patent application for its proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform, designed to enhance nasal drug delivery. This technology aims to improve drug absorption and retention on the nasal mucosa thro

Tone
Positive 71/100
Event
Analyst action
Published
17 Jun 2026 12:39
Source
The Manila Times
Stock Titan Direct company coverage

Polyrizon patent published for nasal drug-delivery technology

Polyrizon (Nasdaq: PLRZ) has announced the publication of its U.S. patent application US 2024/0358741 A1 for its proprietary Trap & Target™ mucoadhesive polymer platform, designed for enhanced nasal drug delivery. This technology aims to improve mucosal retention, drug absorption

Tone
Positive 71/100
Event
Analyst action
Published
17 Jun 2026 12:39
Source
Stock Titan
TradingKey Direct company coverage

Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Polyrizon Ltd (PLRZ), covering its support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and KDJ, alongside moving averages (MA5 to MA200), offering buy, sell, or neutral signals

Tone
Negative 39/100
Event
Market update
Published
17 Jun 2026 11:39
Source
TradingKey
TradingKey Direct company coverage

Polyrizon Ltd (PLRZ) Institutional Confidence

This article provides institutional confidence data for Polyrizon Ltd (PLRZ), showing a current share price of $13.000, up 13.54%. It details institutional shareholding with Izraeli (Tomer) holding 8.00 shares and notes a previous confidence score of 0.00 with no change. The cont

Tone
Positive 63/100
Event
Market update
Published
17 Jun 2026 04:39
Source
TradingKey
TradingKey Direct company coverage

Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Polyrizon Ltd (PLRZ), detailing its current stock price and market capitalization. It highlights that no specific earnings per share (EPS), revenue, net profit, or EBIT forecast data is currently available from the company. The page

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 21:09
Source
TradingKey
Stock Titan Direct company coverage

Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path

Polyrizon Ltd. (PLRZ) has initiated a human performance and characterization study for its NASARIX™ (PL-14) Allergy Blocker. This study, conducted with a European medical center and a CRO, will assess how long the intranasal hydrogel remains in the nasal cavity, providing data cr

Tone
Positive 71/100
Event
Market update
Published
15 Jun 2026 19:39
Source
Stock Titan
Investing.com South Africa Direct company coverage

Polyrizon stock surges on human study for allergy blocker By Investing.com

Polyrizon Ltd (NASDAQ:PLRZ) shares rose 9.2% after the company announced the start of a human study for its NASARIX allergy blocker. The study aims to evaluate the nasal residence time of NASARIX, which is crucial for assessing its protective barrier function against allergens. T

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 14:39
Source
Investing.com South Africa
The Manila Times Direct company coverage

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon, a biotech company, announced a human study for its NASARIX™ (PL-14) Allergy Blocker to evaluate its nasal residence time, a crucial aspect of its protective barrier function. This study, conducted in collaboration with a European medical center and a CRO, will support

Tone
Positive 70/100
Event
Regulatory and legal
Published
15 Jun 2026 12:39
Source
The Manila Times